Efficient cross-presentation of soluble exogenous antigens introduced into dendritic cells using a weak-based amphiphilic peptide

Nobuhito Ikeuchi, Junichiro Futami, Akihiro Hosoi, Shuichi Noji, Makoto Kurachi, Satoshi Ueha, Shin ichiro Fujii, Hidenori Yamada, Koji Matsushima, Fuminori Moriyasu, Kazuhiro Kakimi

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

To develop a novel dendritic cell (DC)-based vaccine for inducing antigen-specific CD8+ T cell responses by cross-presentation, we tested a novel antigen delivery system that introduces soluble antigens into the cytosol of cells by an endocytosis-mediated mechanism which avoids damaging the plasma membrane ("Endo-Porter"™). Proteins released from endosomes into the cytoplasm are degraded by the proteasome, and fragmented antigenic peptides are presented to the classical cytosolic MHC class I pathway. DCs pulsed with OVA protein in the presence of Endo-Porter efficiently stimulate OVA peptide-specific CD8+ T (OT-I) cells. Although this agent diverts some of the endocytosed antigens away from the classical MHC class II-restricted presentation pathway to the class I pathway, the activation of CD4+ T cells was found not to be hampered by Endo-Porter-mediated antigen delivery. On the contrary, it was rather augmented, probably due to the increased uptake of antigen. Because specific CD4+ T cell help is required to license DCs for cross-priming, Endo-Porter-mediated antigen delivery is a promising approach for developing more efficient cancer vaccines targeting both CD4+ and CD8+ T cells.

Original languageEnglish
Pages (from-to)217-222
Number of pages6
JournalBiochemical and Biophysical Research Communications
Volume392
Issue number2
DOIs
Publication statusPublished - Feb 5 2010

Fingerprint

Cross-Priming
Dendritic Cells
T-cells
Antigens
Peptides
T-Lymphocytes
Endocytosis
CD8 Antigens
Cancer Vaccines
Endosomes
Proteasome Endopeptidase Complex
Licensure
Cytosol
Cell membranes
Cytoplasm
Proteins
Vaccines
Cell Membrane
Chemical activation
Endo-Porter

Keywords

  • Cross-presentation
  • DC vaccine
  • Dendritic cell
  • Endo-Porter

ASJC Scopus subject areas

  • Biochemistry
  • Biophysics
  • Cell Biology
  • Molecular Biology

Cite this

Efficient cross-presentation of soluble exogenous antigens introduced into dendritic cells using a weak-based amphiphilic peptide. / Ikeuchi, Nobuhito; Futami, Junichiro; Hosoi, Akihiro; Noji, Shuichi; Kurachi, Makoto; Ueha, Satoshi; Fujii, Shin ichiro; Yamada, Hidenori; Matsushima, Koji; Moriyasu, Fuminori; Kakimi, Kazuhiro.

In: Biochemical and Biophysical Research Communications, Vol. 392, No. 2, 05.02.2010, p. 217-222.

Research output: Contribution to journalArticle

Ikeuchi, Nobuhito ; Futami, Junichiro ; Hosoi, Akihiro ; Noji, Shuichi ; Kurachi, Makoto ; Ueha, Satoshi ; Fujii, Shin ichiro ; Yamada, Hidenori ; Matsushima, Koji ; Moriyasu, Fuminori ; Kakimi, Kazuhiro. / Efficient cross-presentation of soluble exogenous antigens introduced into dendritic cells using a weak-based amphiphilic peptide. In: Biochemical and Biophysical Research Communications. 2010 ; Vol. 392, No. 2. pp. 217-222.
@article{8b9dcb752fba4bffba890387b6b792c5,
title = "Efficient cross-presentation of soluble exogenous antigens introduced into dendritic cells using a weak-based amphiphilic peptide",
abstract = "To develop a novel dendritic cell (DC)-based vaccine for inducing antigen-specific CD8+ T cell responses by cross-presentation, we tested a novel antigen delivery system that introduces soluble antigens into the cytosol of cells by an endocytosis-mediated mechanism which avoids damaging the plasma membrane ({"}Endo-Porter{"}™). Proteins released from endosomes into the cytoplasm are degraded by the proteasome, and fragmented antigenic peptides are presented to the classical cytosolic MHC class I pathway. DCs pulsed with OVA protein in the presence of Endo-Porter efficiently stimulate OVA peptide-specific CD8+ T (OT-I) cells. Although this agent diverts some of the endocytosed antigens away from the classical MHC class II-restricted presentation pathway to the class I pathway, the activation of CD4+ T cells was found not to be hampered by Endo-Porter-mediated antigen delivery. On the contrary, it was rather augmented, probably due to the increased uptake of antigen. Because specific CD4+ T cell help is required to license DCs for cross-priming, Endo-Porter-mediated antigen delivery is a promising approach for developing more efficient cancer vaccines targeting both CD4+ and CD8+ T cells.",
keywords = "Cross-presentation, DC vaccine, Dendritic cell, Endo-Porter",
author = "Nobuhito Ikeuchi and Junichiro Futami and Akihiro Hosoi and Shuichi Noji and Makoto Kurachi and Satoshi Ueha and Fujii, {Shin ichiro} and Hidenori Yamada and Koji Matsushima and Fuminori Moriyasu and Kazuhiro Kakimi",
year = "2010",
month = "2",
day = "5",
doi = "10.1016/j.bbrc.2010.01.019",
language = "English",
volume = "392",
pages = "217--222",
journal = "Biochemical and Biophysical Research Communications",
issn = "0006-291X",
publisher = "Academic Press Inc.",
number = "2",

}

TY - JOUR

T1 - Efficient cross-presentation of soluble exogenous antigens introduced into dendritic cells using a weak-based amphiphilic peptide

AU - Ikeuchi, Nobuhito

AU - Futami, Junichiro

AU - Hosoi, Akihiro

AU - Noji, Shuichi

AU - Kurachi, Makoto

AU - Ueha, Satoshi

AU - Fujii, Shin ichiro

AU - Yamada, Hidenori

AU - Matsushima, Koji

AU - Moriyasu, Fuminori

AU - Kakimi, Kazuhiro

PY - 2010/2/5

Y1 - 2010/2/5

N2 - To develop a novel dendritic cell (DC)-based vaccine for inducing antigen-specific CD8+ T cell responses by cross-presentation, we tested a novel antigen delivery system that introduces soluble antigens into the cytosol of cells by an endocytosis-mediated mechanism which avoids damaging the plasma membrane ("Endo-Porter"™). Proteins released from endosomes into the cytoplasm are degraded by the proteasome, and fragmented antigenic peptides are presented to the classical cytosolic MHC class I pathway. DCs pulsed with OVA protein in the presence of Endo-Porter efficiently stimulate OVA peptide-specific CD8+ T (OT-I) cells. Although this agent diverts some of the endocytosed antigens away from the classical MHC class II-restricted presentation pathway to the class I pathway, the activation of CD4+ T cells was found not to be hampered by Endo-Porter-mediated antigen delivery. On the contrary, it was rather augmented, probably due to the increased uptake of antigen. Because specific CD4+ T cell help is required to license DCs for cross-priming, Endo-Porter-mediated antigen delivery is a promising approach for developing more efficient cancer vaccines targeting both CD4+ and CD8+ T cells.

AB - To develop a novel dendritic cell (DC)-based vaccine for inducing antigen-specific CD8+ T cell responses by cross-presentation, we tested a novel antigen delivery system that introduces soluble antigens into the cytosol of cells by an endocytosis-mediated mechanism which avoids damaging the plasma membrane ("Endo-Porter"™). Proteins released from endosomes into the cytoplasm are degraded by the proteasome, and fragmented antigenic peptides are presented to the classical cytosolic MHC class I pathway. DCs pulsed with OVA protein in the presence of Endo-Porter efficiently stimulate OVA peptide-specific CD8+ T (OT-I) cells. Although this agent diverts some of the endocytosed antigens away from the classical MHC class II-restricted presentation pathway to the class I pathway, the activation of CD4+ T cells was found not to be hampered by Endo-Porter-mediated antigen delivery. On the contrary, it was rather augmented, probably due to the increased uptake of antigen. Because specific CD4+ T cell help is required to license DCs for cross-priming, Endo-Porter-mediated antigen delivery is a promising approach for developing more efficient cancer vaccines targeting both CD4+ and CD8+ T cells.

KW - Cross-presentation

KW - DC vaccine

KW - Dendritic cell

KW - Endo-Porter

UR - http://www.scopus.com/inward/record.url?scp=75749131972&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=75749131972&partnerID=8YFLogxK

U2 - 10.1016/j.bbrc.2010.01.019

DO - 10.1016/j.bbrc.2010.01.019

M3 - Article

C2 - 20067764

AN - SCOPUS:75749131972

VL - 392

SP - 217

EP - 222

JO - Biochemical and Biophysical Research Communications

JF - Biochemical and Biophysical Research Communications

SN - 0006-291X

IS - 2

ER -